Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma

Extrahepatic Cholangiocarcinoma Clinical Trial

Official title:

The CLEAN-DUCT / TRITICC-3 Trial - Phase IIa, Prospective, Single Arm, Open Label, Non-randomized, Multi-center Pilot Study of Durvalumab (MEDI4736) + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06440993
• Other study ID #: CLEAN-DUCT / TRITICC-3
• Secondary ID: 2023-509165-21-0
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: July 2024
• Est. completion date: April 2028

Study information

• Verified date: June 2024
• Source: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
• Contact: Christoph Roderburg, Prof. Dr.
• Phone: +49 211 8108030
• Email: christoph.roderburg[@]med.uni-duesseldorf.de
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The present clinical trial is a prospective, investigator-initiated, single-arm, open-label, multicenter phase II trial. Patients with unresectable perihilar and/or ductal CCA with indication for bile duct stenting and palliative systemic therapy as determined by the local multidisciplinary team (MDT), who already resolved cholestasis due to RFA + Stent will be enrolled. We hypothesize that in patients with extrahepatic cholangiocarcinoma, the use of a combination radiofrequency ablation followed by systemic treatment with chemotherapy plus durvalumab might further increase the anti-tumor activity.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 42
• Est. completion date: April 2028
• Est. primary completion date: January 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patient* has given written informed consent.

2. Patient is = 18 years of age at time of signing the written informed consent.

3. Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.

4. Patient has been diagnosed with histologically or cytologically confirmed

1. histologically or cytologically confirmed cholangiocarcinoma as adenocarcinoma of pancreatobiliary type

2. unresectable perihilar and/or ductal cholangiocarcinoma with indication for bile duct stenting and palliative systemic therapy as determined by the local multidisciplinary team (MDT) and already resolved cholestasis due to RFA + stent

5. Patient tolerated RFA prior to inclusion and is eligible for repeat RFA during the study (does not have any contraindications) as determined by investigator.

6. Patient is eligible for palliative systemic therapy based on clinical and laboratory parameters (except hyperbilirubinemia) as determined by the local MDT

7. Patient has a ECOG = 1.

8. Patient has life expectancy of = 12 weeks

9. Patient has body weight > 30 kg

10. Adequate blood count, liver-enzymes, and renal function:

1. ANC > 1,500 cells/µL without the use of hematopoietic growth factors

2. Platelet count = 100 x 109/L (>100,000 per mm3)

3. Hemoglobin = 9 g/dL

4. Serum total bilirubin = 3x upper normal limit (ULN) (biliary drainage is allowed for biliary obstruction; elevated bilirubin should be caused by obstruction not impaired liver function as assessed by albumin and INR values)

5. Albumin levels = 2.8 g/dL

6. Patients not receiving therapeutic anticoagulation must have an INR< 2.0 ULN and PTT < 1.5 ULN within 7 days prior to randomization. The use of full dose anticoagulants is allowed as long as the INR or PTT is within therapeutic limits (according to the medical standard in the institution) and the patient has been on a stable dose for anticoagulants for at least three weeks at the time of inclusion

7. AST (SGOT)/ALT (SGPT) = 2.5 x institutional ULN unless liver metastases are present, in which case it must be = 5x ULN

8. Serum Creatinine = 1.5 x ULN and a calculated creatinine clearance rate = 60 mL /min

11. Female patients defined as women of childbearing potential (WOCBP) or male patients with WOCBP partners must agree to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of <1% per year during the treatment period and for at least 6 months after the last dose of chemotherapy or for at least 3 months after last dose of durvalumab, whatever happens last. Male patients must refrain from donating sperm during this same period. Male patients with a pregnant partner must agree to remain abstinent or to use a condom for the duration of the pregnancy.

Exclusion Criteria:

1. Patient received previous or simultaneous endobiliary treatment other than RFA (e.g. PDT or brachytherapy)

2. Patient received previous systemic therapy with a PD-1, PD-L1 inhibitor (including durvalumab) or CTLA4 inhibitor or classical chemotherapy agents like platinum, fluoropyrimidine or gemcitabine-based regimens.

3. Patient receives any concurrent chemotherapy, investigational product or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer related conditions (e.g., hormone replace therapy) is acceptable.

4. Patient has known hypersensitivity to any component of the durvalumab formulation as well as a known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion protein and/or any known contraindication (including hypersensitivity) to gemcitabine or cisplatin.

5. Patient has history of primary immunodeficiency

6. Patient has stage B cirrhosis according to Child-Pugh criteria (or worse) or cirrhosis (of any grade) with a history of hepatic encephalopathy or clinically significant ascites resulting from cirrhosis. Clinically significant ascites is defined as ascites resulting from cirrhosis requiring diuretics or paracentesis.

7. Patient has any unresolved NCI CTCAE grade = 2 from previous anticancer therapy with the exception of alopecia, vitiligo, and laboratory values defined in the inclusion criteria

1. Patients with grade = 2 neuropathy will be evaluated on a case-by-case basis after consultation with the Lead Investigator

2. Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab may be included only after consultation with the Lead Investigator.

8. Patient had a prior allogeneic bone marrow transplantation or prior solid organ transplantation.

9. Patient has active or history of autoimmune or inflammatory disorders (including, but not limited to, inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves'

disease, rheumatoid arthritis, hypophysitis, uveitis]) . The following are exceptions:

1. Patients with vitiligo or alopecia

2. Patients with hypothyroidism (e.g. following Hashimoto syndrome) stable on hormone replacement

3. Patients with any chronic skin condition that does not require systemic therapy

4. Patients with celiac disease controlled by diet alone

5. Patients without active disease in the last 5 years may be included but only after consultation with the Lead Investigator

10. Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent

Related Conditions & MeSH terms

• Cholangiocarcinoma
• Extrahepatic Cholangiocarcinoma

Intervention

Drug:
• Gemcitabine
Gemcitabine, 1,000 mg/m2 IV
• Cisplatin
Cisplatin, 25 mg/m2 IV
• Durvalumab
Durvalumab, 1,500 mg IV

Procedure:
• ID-RFA
endoscopic intraductal RFA

Locations

Country	Name	City	State
Germany	Universitätsklinikum Düsseldorf	Düsseldorf
Germany	Universitätsklinikum Köln	Köln

Sponsors (4)

Lead Sponsor	Collaborator
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	AstraZeneca, Universitätsklinikum Düsseldorf, Germany, Universitätsklinikum Köln, Germany

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall survival rate	Overall survival rate after 12 months (OS@12months) defined as proportion of patients alive 12 months after enrollment	at 12 months
Secondary	Progression-free survival (PFS)	Progression-free survival (PFS) defined as time from enrollment to the date of disease progression or death from any cause	at study end
Secondary	Overall survival (OS)	Overall survival (OS) Defined as time from enrollment to the date of death from any cause	at study end
Secondary	Incidence and nature of adverse events using NCI CTCAE 5.0	Assessment of safety of the treatment as determined by the incidence, nature, causality, frequency, timing and severity of adverse events using NCI CTCAE 5.0	through study completion, up to 3years
Secondary	Time to cholangitis	Time to cholangitis Defined as time from enrollment to the date of confirmed cholangitis	from enrollment to first cholangitis event, up to 3 years
Secondary	To assess quality of life (QoL) data from patients using EORTC QLQ-BIL21	To assess quality of life (QoL) data from patients using EORTC QLQ-BIL21	through study completion, up to 3years
Secondary	To assess quality of life (QoL) data from patients using EORTC QLQ-C30	To assess quality of life (QoL) data from patients using EORTC QLQ-C30	through study completion, up to 3years